Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts This week, 27 April 2025: Treatment-resistant hypertension Influenza transmission Nanoplastics in human brains Malaria elimination Chikungunya vaccine

Lung Cancer

Free Subscription 10.03.2025 1 AJR Am J Roentgenol 5 Ann Surg Oncol 1 Ann Thorac Surg 3 Anticancer Res 7 BMC Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 3 Cancer Sci 1 Carcinogenesis 1 Clin Cancer Res 3 Clin Lung Cancer 1 Clin Nucl Med 2 Eur J Cancer 1 Eur Respir J 1 Int J Oncol 1 J Clin Invest 1 J Clin Oncol 1 J Thorac Cardiovasc Surg 4 J Thorac Oncol 1 Lancet Oncol 9 Lung Cancer 2 Mol Cancer Ther 1 Mol Carcinog 1 Oncol Rep 2 Oncologist 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. JEONG YJ
   Risk-Based Selection for Invasive Mediastinal Staging in Nonsmall Cell Lung Cancer: Role of Preoperative Imaging.
   AJR Am J Roentgenol. 2025 Mar 5. doi: 10.2214/AJR.25.32890.
   PubMed        
   
   

   
   Ann Surg Oncol

2. MADEKA I, Mack SJ, Rshaidat H, Ishwar A, et al
   Medicaid Expansion is Associated with Differences in Local Therapy for Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Mar 5. doi: 10.1245/s10434-025-17082.
   PubMed         Abstract available
   
   
3. BASKIN AS, Burapachaisri K, Guha S, Velotta JB, et al
   The Landmark Series: Advances in Preoperative Mediastinal Lymph Node Staging for Non-small Cell Lung Cancer (NSCLC).
   Ann Surg Oncol. 2025 Mar 1. doi: 10.1245/s10434-025-17008.
   PubMed         Abstract available
   
   
4. MATSUDO K, Takada K, Hashinokuchi A, Nagano T, et al
   Significance of Tumor Microvasculature in the Tumor Microenvironment in Adenocarcinoma with EGFR Common Mutations.
   Ann Surg Oncol. 2025;32:3031-3039.
   PubMed         Abstract available
   
   
5. LIANG XL, Su YD, Li XB, Fu YB, et al
   Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.
   Ann Surg Oncol. 2025;32:2912-2922.
   PubMed         Abstract available
   
   
6. CHEN PH, Chen C, Lu CW, Lu TP, et al
   Tumor Spread Through Air Spaces Predicts Survival in Resected Pulmonary Lymphoepithelial Carcinoma.
   Ann Surg Oncol. 2025;32:2675-2686.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

7. VERGE R, Rouch A, Rabinel P, Renaud C, et al
   Evaluation of uncertain resection for localized non-small cell lung cancer: the crucial prognosis of suboptimal lymph node assessment.
   Ann Thorac Surg. 2025 Feb 27:S0003-4975(25)00170.
   PubMed         Abstract available
   
   

   
   Anticancer Res

8. TONE M, Isono T, Yamamoto Y, Takeda Y, et al
   Peripheral CD4(+) T Cells Predict T Cell Immunity in Lung Tissues of Non-small Cell Lung Cancer Patients.
   Anticancer Res. 2025;45:909-920.
   PubMed         Abstract available
   
   
9. WATANABE H, Nakamura S, Imamura Y, Okado S, et al
   Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung Cancer Patients With Microscopic Residual Disease.
   Anticancer Res. 2025;45:1193-1204.
   PubMed         Abstract available
   
   
10. YUI M, Nakamura S, Koike Y, Hirota K, et al
    Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:1105-1115.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. NIE X, Zou M, Song C, Zhang P, et al
    Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.
    BMC Cancer. 2025;25:393.
    PubMed         Abstract available
    
    
12. SHIMA Y, Yoshida H, Suminaga K, Yoshida H, et al
    Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.
    BMC Cancer. 2025;25:388.
    PubMed         Abstract available
    
    
13. ZHI L, Zhang Z, Gao Q, Shang C, et al
    Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
    BMC Cancer. 2025;25:386.
    PubMed        
    
    
14. OH JH, Lee SJ, Park YJ
    F-18 FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell lung cancer.
    BMC Cancer. 2025;25:379.
    PubMed         Abstract available
    
    
15. ZHANG L, Luo J, Wu X
    Impact of single-port versus three-port video-assisted thoracic surgery lobectomy on postoperative pain and quality of life in early-stage non-small cell lung cancer patients: a meta-analysis.
    BMC Cancer. 2025;25:400.
    PubMed         Abstract available
    
    
16. LAI Y, Zhou S, Tian L, Li H, et al
    Preoperative heart rate variability as a predictor of postoperative pneumonia and lung function recovery in surgical lung cancer patients: a prospective observed study.
    BMC Cancer. 2025;25:404.
    PubMed         Abstract available
    
    
17. LAI Z, Pang Y, Zhou Y, Chen L, et al
    Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy.
    BMC Cancer. 2025;25:411.
    PubMed         Abstract available
    
    

    
    Cancer

18. SHIELDS MD, Chiang AC, Byers LA
    Top advances of the year: Small cell lung cancer.
    Cancer. 2025;131:e35770.
    PubMed         Abstract available
    
    

    
    Cancer Lett

19. FU R, Zhang C, Song MM, Gao X, et al
    A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment.
    Cancer Lett. 2025;616:217595.
    PubMed         Abstract available
    
    

    
    Cancer Res

20. SOS ML, Koker M, Weir BA, Heynck S, et al
    Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR.
    Cancer Res. 2025;85:1003.
    PubMed        
    
    

    
    Cancer Sci

21. CHEN Y, Pan G, Yang Y, Wu H, et al
    Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.
    Cancer Sci. 2025;116:792-807.
    PubMed         Abstract available
    
    
22. ZHU P, Li Z, Sun Y, Liu T, et al
    Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.
    Cancer Sci. 2025;116:581-591.
    PubMed         Abstract available
    
    
23. ZHANG Y, Xu Y, Xu J, Zhong H, et al
    Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
    Cancer Sci. 2025;116:753-763.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

24. LI J, Li Y, Wang X, Zhou Z, et al
    Germline alteration analysis reveals EPHB4R91H mutation as a key player in multiple primary lung tumors.
    Carcinogenesis. 2025;46:bgae074.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

25. TRONTZAS IP, He M, Wurtz A, Robbins CJ, et al
    Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

26. SHAH M, Noronha V, Patil V, Singh AK, et al
    Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients.
    Clin Lung Cancer. 2025 Feb 11:S1525-7304(25)00026.
    PubMed         Abstract available
    
    
27. TRISOLINI R, Cetoretta V, Sotgiu G, Cancellieri A, et al
    Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular Characteristics.
    Clin Lung Cancer. 2025 Feb 8:S1525-7304(25)00033.
    PubMed         Abstract available
    
    
28. BARRICHELLO APC, Elkrief A, Ricciuti B, Ganta T, et al
    Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (>/=50%) Patients.
    Clin Lung Cancer. 2025 Feb 4:S1525-7304(25)00025.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

29. CUI Y, Zhou X, Guan X, Li N, et al
    Pulmonary Metastases From Early-stage Granulosa Cell Tumor 15 Years Later on 18F-NOTA-FAPI-04 and 18F-FDG PET/CT.
    Clin Nucl Med. 2025 Mar 3. doi: 10.1097/RLU.0000000000005801.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

30. LANCASTER HL, Jiang B, Davies MPA, Gratama JWC, et al
    Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction.
    Eur J Cancer. 2025;220:115324.
    PubMed         Abstract available
    
    
31. LANCASTER HL, Walstra ANH, Myers K, Avila RS, et al
    Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer.
    Eur J Cancer. 2025;220:115323.
    PubMed         Abstract available
    
    

    
    Eur Respir J

32. RATSIHORIMANANA R, Maitre T, Dusselier M, Triet Ngo M, et al
    Recurrent respiratory papillomatosis in adults with lower respiratory tract involvement: a retrospective study of the OrphaLung and GETIF networks.
    Eur Respir J. 2025;65:2400618.
    PubMed         Abstract available
    
    

    
    Int J Oncol

33. KAEWPIBOON C, Surapinit S, Malilas W, Moon E, et al
    [Retracted] Feroniellin A?induced autophagy causes apoptosis in multidrug?resistant human A549 lung cancer cells.
    Int J Oncol. 2025;66:30.
    PubMed         Abstract available
    
    

    
    J Clin Invest

34. PARDO L, Norman JC
    Targeting the secretory program of 3q-amplified lung cancers.
    J Clin Invest. 2024;134:e181798.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. KINDLER HL, Ismaila N, Bazhenova L, Chu Q, et al
    Treatment of Pleural Mesothelioma: ASCO Guideline Update.
    J Clin Oncol. 2025;43:1006-1038.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

36. CHO AR, Najafi T, Ramanakumar AV, Ferri L, et al
    The Effect of Multimodal Prehabilitation on Postoperative Outcomes in Lung Cancer Surgery.
    J Thorac Cardiovasc Surg. 2025 Mar 3:S0022-5223(25)00173.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

37. MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al
    Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Thorac Oncol. 2025;20:285-295.
    PubMed         Abstract available
    
    
38. BROWN M, Myers R, Lam S
    Enlarging the Reach of Screening and Early Detection of Lung Cancer.
    J Thorac Oncol. 2025;20:249-251.
    PubMed        
    
    
39. CHOU TY, Dacic S, Wistuba I, Beasley MB, et al
    Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2025;20:311-330.
    PubMed         Abstract available
    
    
40. LU S, Wu L, Wang Q, Wang Z, et al
    Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    J Thorac Oncol. 2025;20:366-382.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

41. LI Z, Wang Y, Sun Y, Wang L, et al
    Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
    Lancet Oncol. 2025 Feb 25:S1470-2045(25)00012.
    PubMed         Abstract available
    
    

    
    Lung Cancer

42. GROS L, Yip R, Flores RM, Zhang J, et al
    Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage 1A Non-Small cell lung cancer.
    Lung Cancer. 2025;202:108465.
    PubMed         Abstract available
    
    
43. SAW SPL, Takano A, Zhou S, Hlaing NO, et al
    EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.
    Lung Cancer. 2025;202:108463.
    PubMed         Abstract available
    
    
44. SATOH H, Okuma Y, Shinno Y, Masuda K, et al
    Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies.
    Lung Cancer. 2025;202:108453.
    PubMed         Abstract available
    
    
45. ZHANG M, Deng C, Fu F, Li Y, et al
    Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data.
    Lung Cancer. 2025;201:108451.
    PubMed         Abstract available
    
    
46. MORIMOTO K, Yamada T, Furuya N, Tanaka H, et al
    Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
    Lung Cancer. 2025;201:108447.
    PubMed         Abstract available
    
    
47. CHOI W, Lee W, Kim Y, Lee SJ, et al
    Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma.
    Lung Cancer. 2025;201:108448.
    PubMed         Abstract available
    
    
48. SUBRAMANIAN J, Gregg J, Berktas M, Li J, et al
    EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database.
    Lung Cancer. 2025;201:108412.
    PubMed         Abstract available
    
    
49. CAMIDGE DR, Sugawara S, Kondo M, Kim HR, et al
    Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
    Lung Cancer. 2025;201:108424.
    PubMed         Abstract available
    
    
50. YAO Z, Qiu T, Li C, Kong W, et al
    Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases.
    Lung Cancer. 2025;201:108414.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

51. KIM DK, Synn CB, Lee W, Jo HN, et al
    Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
    Mol Cancer Ther. 2025;24:354-369.
    PubMed         Abstract available
    
    
52. KOGAI H, Tsukamoto S, Koga M, Miyano M, et al
    Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models.
    Mol Cancer Ther. 2025;24:392-405.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

53. MAO S, Li Q, Yang Y, Liu Z, et al
    Potential Crosstalk Between ANXA1+ Epithelial Cells and FABP4+ TAM Cells of Ferroptosis-Related Molecular Clusters Promotes an Immunosuppressive Microenvironment in Non-Small Cell Lung Cancer.
    Mol Carcinog. 2025 Mar 4. doi: 10.1002/mc.23899.
    PubMed         Abstract available
    
    

    
    Oncol Rep

54. ZHANG L, Wang S, Wang L
    Pan?cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma.
    Oncol Rep. 2025;53:50.
    PubMed         Abstract available
    
    

    
    Oncologist

55. SALDANHA EF, Cordeiro de Lima VC, Fares A, Corassa M, et al
    Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).
    Oncologist. 2025;30:oyae347.
    PubMed         Abstract available
    
    
56. RESTIVO L, Rochigneux P, Bouhnik AD, Arciszewski T, et al
    Patients' psychosocial attributes and aggressiveness of cancer treatments near the end of life.
    Oncologist. 2025;30:oyae317.
    PubMed         Abstract available
    
    

    
    PLoS One

57. PAN X, Togka K, Ten Berge H, de Jong L, et al
    Lung cancer screening with volume computed tomography is cost-effective in Greece.
    PLoS One. 2025;20:e0316351.
    PubMed         Abstract available
    
    
58. GHIROTTO L, Paci E, Bricci C, Marini S, et al
    Self-blaming as a barrier to lung cancer screening and smoking cessation programs in Italy. A qualitative study.
    PLoS One. 2025;20:e0318732.
    PubMed         Abstract available
    
    
59. 
    Retraction: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer.
    PLoS One. 2025;20:e0320171.
    PubMed        
    
    

    
    Proc Natl Acad Sci U S A

60. SAXENA T, Quan A, Chan E, Kozlova N, et al
    EGFR-induced lncRNA TRIDENT promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair.
    Proc Natl Acad Sci U S A. 2025;122:e2415389122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.